CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OutMARCH is pioneering a new protein degradation technology using engineered antibodies to selectively target and eliminate harmful proteins in cancer cells. This approach aims to address treatment-resistant cancers by degrading proteins that conventional therapies cannot target.
The OutMARCH project pioneers a paradigm-shifting protein degradation technology aimed at transforming the therapeutic landscape for cancer and beyond.
By engineering a novel class of bispecific antibodies—SureTACs—that harness membrane-bound E3 ubiquitin ligases to selectively degrade disease-driving surface proteins.
This groundbreaking lysosomal-targeting approach offers greater selectivity, durability, and breadth than conventional blocking therapies and, moreover, enables the targeting of p…
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Bonn
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Zurich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Utrecht
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
